Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Edgar Carnero Contentti & Jorge Correale. (2022) Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis. Drug Design, Development and Therapy 16, pages 3473-3490.
Read now
Read now
Tony Eight Lin, Li-Chin Sung, Min-Wu Chao, Min Li, Jia-Huei Zheng, Tzu-Ying Sung, Jui-Hua Hsieh, Chia-Ron Yang, Hsueh-Yun Lee, Er-Chieh Cho & Kai-Cheng Hsu. (2022) Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 226-235.
Read now
Read now
Edgar Carnero Contentti & Jorge Correale. (2020) Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opinion on Emerging Drugs 25:4, pages 377-381.
Read now
Read now
Tsering Gyalpo Lama, Daniel Kyung & Susan O’Brien. (2020) Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Expert Review of Hematology 13:8, pages 871-883.
Read now
Read now
Articles from other publishers (39)
Tingting Liang, Lifang Cen, Junjie Wang, Ming Cheng, Weibo Guo, Wenjie Wang, Chunqiu Yu, Haifeng Zhang, Yuan Wang, Zhongyan Hao, Jiaming Jin, Yaoyao Wu, Teng Jiang, Qihua Zhu & Yungen Xu. (2023) Discovery of novel dual Bruton’s tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis. Bioorganic & Medicinal Chemistry 96, pages 117354.
Crossref
Crossref
David Y. Lin & Amy H. Andreotti. (2023) Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. PLOS ONE 18:8, pages e0290872.
Crossref
Crossref
Olga Gumkowska-Sroka, Kacper Kotyla, Ewa Mojs, Klaudia Palka & Przemysław Kotyla. (2023) Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. Pharmaceuticals 16:8, pages 1066.
Crossref
Crossref
Haofan Zhang, Fengming He, Guiping Gao, Sheng Lu, Qiaochu Wei, Hongyu Hu, Zhen Wu, Meijuan Fang & Xiumin Wang. (2023) Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules 28:3, pages 943.
Crossref
Crossref
卓如 周. (2023) Review of the Efficacy of Bruton Tyrosine Kinase (BTK) Inhibitors on Primary Central Nervous System Lymphoma. Advances in Clinical Medicine 13:01, pages 1083-1091.
Crossref
Crossref
Shuwirda Boon Seen, Yu Gong & Mark Ashton. 2023.
1
85
.
Dejan Jakimovski, Bianca Weinstock-Guttman & Robert Zivadinov. 2023. Translational Neuroimmunology, Volume 8. Translational Neuroimmunology, Volume 8
175
189
.
Tanuj Sharma, Venu Venkatarame Gowda Saralamma, Duk Chul Lee, Mohammad Azhar Imran, Jaehyuk Choi, Mohammad Hassan Baig & Jae-June Dong. (2022) Combining structure-based pharmacophore modeling and machine learning for the identification of novel BTK inhibitors. International Journal of Biological Macromolecules 222, pages 239-250.
Crossref
Crossref
João Figueira Scarini, Luccas Lavareze, Reydson Alcides de Lima-Souza, Carolina Emerick, Mayara Trevizol Gonçalves, Tayná Figueiredo-Maciel, Gustavo de Souza Vieira, Talita de Carvalho Kimura, Raisa Sales de Sá, Iara Gonçalves Aquino, Patricia Maria Fernandes, Luiz Paulo Kowalski, Albina Altemani, Fernanda Viviane Mariano & Erika Said Abu Egal. (2022) Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. Critical Reviews in Oncology/Hematology 180, pages 103863.
Crossref
Crossref
Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Genesis M. Bacani, Jianmei Wei, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Leon Chang, Kathleen W. Clancy, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, Jiejun Wu, Haopeng Rui, Kia Sepassi, Marcello Gaudiano, Mariette Bekkers, Ivo Cornelissen, Kathryn Packman, Mark Seierstad, Christos Xiouras, Scott D. Bembenek, Richard Alexander, Cynthia Milligan, Sriram Balasubramanian, Alec D. Lebsack, Jennifer D. Venable, Ulrike Philippar, James P. Edwards & Gavin Hirst. (2022) Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry 65:21, pages 14326-14336.
Crossref
Crossref
Debasis Das, Jingbing Wang & Jian Hong. (2022) Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially
Targeting BTK C481S Mutation- Recent Developments and Perspectives. Current Topics in Medicinal Chemistry 22:20, pages 1674-1691.
Crossref
Crossref
Jingyu Zhang, Jinxin Che, Xiaomin Luo, Mingfei Wu, Weijuan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang, Shenxin Zeng, Weihao Zhuang, Yizhe Wu, Yongjin Xu, Yubo Zhou, Jia Li & Xiaowu Dong. (2022) Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma. Journal of Medicinal Chemistry 65:13, pages 9096-9125.
Crossref
Crossref
Mohammad Almasri, Marah Amer, Joseph Ghanej, Abdurraouf Mokhtar Mahmoud, Gianluca Gaidano & Riccardo Moia. (2022) Druggable Molecular Pathways in Chronic Lymphocytic Leukemia. Life 12:2, pages 283.
Crossref
Crossref
Fansheng Ran, Yun Liu, Chen Wang, Zhongyuan Xu, Yanan Zhang, Yang Liu, Guisen Zhao & Yong Ling. (2022) Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. European Journal of Medicinal Chemistry 229, pages 114009.
Crossref
Crossref
Cathy Muste & Chungang Gu. (2022) BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS. Drug Metabolism and Pharmacokinetics 42, pages 100433.
Crossref
Crossref
Dou Dou, Wenjie Sha, Yanyan Diao, Rongrong Su, Yunjin Qiao, Zhixiao Yu, Zhenjiang Zhao, Honglin Li, Zhuo Chen & Yufang Xu. (2022) Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton’s tyrosine kinase (BTK) inhibitors. Bioorganic Chemistry 119, pages 105541.
Crossref
Crossref
Hui Qiu, Zahid Ali, Julian Bowlan, Richard Caldwell, Anna Gardberg, Nina Glaser, Andreas Goutopoulos, Jared Head, Theresa Johnson, Christine Maurer, Katrin Georgi, Roland Grenningloh, Zhizhou Fang, Federica Morandi, Felix Rohdich, Ralf. Schmidt, Ariele Viacava Follis & Brian Sherer. (2021) Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity. ChemMedChem 16:24, pages 3653-3662.
Crossref
Crossref
Bruno Tasso, Andrea Spallarossa, Eleonora Russo & Chiara Brullo. (2021) The Development of BTK Inhibitors: A Five-Year Update. Molecules 26:23, pages 7411.
Crossref
Crossref
Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr & Bruno Cenni. (2021) Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science 14:5, pages 1756-1768.
Crossref
Crossref
Datong Zhang, He Gong & Fancui Meng. (2021) Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules 26:16, pages 4907.
Crossref
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Crossref
G.M. Dettorre, M. Patel, A. Gennari, G. Pentheroudakis, E. Romano, A. Cortellini & D.J. Pinato. (2021) The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open 6:3, pages 100123.
Crossref
Crossref
Jingyu Zhang, Yu Zhang, Bingxue Qu, Haiyan Yang, Shengquan Hu & Xiaowu Dong. (2021) If small molecules immunotherapy comes, can the prime be far behind?. European Journal of Medicinal Chemistry 218, pages 113356.
Crossref
Crossref
Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable & James P. Edwards. (2021) Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. ACS Medicinal Chemistry Letters 12:5, pages 782-790.
Crossref
Crossref
Jiakuo Liu, Chengjuan Chen, Dongmei Wang, Jie Zhang & Tiantai Zhang. (2021) Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. European Journal of Medicinal Chemistry 217, pages 113329.
Crossref
Crossref
Fatih M. Uckun & Taracad Venkatachalam. (2021) Targeting Solid Tumors With BTK Inhibitors. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Alexander C. Chacon, Alexa D. Melucci, Shuyang S. Qin & Peter A. Prieto. (2021) Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. International Journal of Molecular Sciences 22:6, pages 3228.
Crossref
Crossref
Zhiyi Zhang, Jie Song, Cao Xie, Jun Pan, Weiyue Lu & Min Liu. (2021) Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials. The AAPS Journal 23:2.
Crossref
Crossref
Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han & Chenzhong Liao. (2021) Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Journal of Medicinal Chemistry 64:3, pages 1283-1345.
Crossref
Crossref
Soňa Krajčovičová, Radek Jorda, David Vanda, Miroslav Soural & Vladimír Kryštof. (2021) 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. European Journal of Medicinal Chemistry 211, pages 113094.
Crossref
Crossref
Raji E Joseph, Neha Amatya, D Bruce Fulton, John R Engen, Thomas E Wales & Amy Andreotti. (2020) Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. eLife 9.
Crossref
Crossref
Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng & Brian T. Hopkins. (2020) Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. Journal of Medicinal Chemistry 63:21, pages 12526-12541.
Crossref
Crossref
Sigrid S. Skånland, Linda Karlsen & Kjetil Taskén. (2020) B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia. Scandinavian Journal of Immunology 92:5.
Crossref
Crossref
Daniel J. Baillache & Asier Unciti-Broceta. (2020)
Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
d
]pyrimidine scaffold
. RSC Medicinal Chemistry 11:10, pages 1112-1135.
Crossref
Crossref
Ronen Gabizon & Nir London. (2020) A Fast and Clean BTK Inhibitor. Journal of Medicinal Chemistry 63:10, pages 5100-5101.
Crossref
Crossref
Jedediah Seltzer, Razia Moorad, Jason M. Schifano, Justin T. Landis & Dirk P. Dittmer. (2020) Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. Journal of Virology 94:10.
Crossref
Crossref
Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen & Nils Jakob Vest Hansen. 2020.
181
249
.
Benjamín Rubio-Jurado, Lluvia Sugey Sosa-Quintero, Ivette Lenina Carrasco-Martinez, Armando Norato-Delgado, Eduardo Garcia-Luna, Sandra Guzmán-Silahua, Carlos Riebeling-Navarro & Arnulfo Hernan Nava-Zavala. 2020.
19
53
.
Neha AmatyaDavid Yin-wei LinAmy H. Andreotti. (2019) Dynamic regulatory features of the protein tyrosine kinases. Biochemical Society Transactions 47:4, pages 1101-1116.
Crossref
Crossref